Subjects
and Methods: Patients (n = 172, aged 28–87 years)
with AMI and left ventricular ejection fraction ≤ 0.45 were
randomized to the nebivolol (n = 55), carvedilol (n = 60) and
metoprolol succinate (n = 57) groups. Baseline demographic
and clinical characteristics and composite event rates of
nonfatal MI, cardiovascular mortality, hospitalization due to
unstable angina pectoris or heart failure, stroke or revascularization
during the 12-month follow-up were compared
among the groups using the χ 2 test, t test or log-rank test as
appropriate.